IAVI C001
Status:Completed
Phase:I
Principal Investigator(s):David Ho, Michael Keefer, Soe Than
Objective:The purpose of this study is to determine the safety and immune response to a investigational DNA Plasmid HIV vaccine, ADVAX e/g + ADVAX p/n-t (ADVAX), at three different dosage levels, in adults who are not infected with HIV.
Prevention Option(s):HIV Vaccine
Study Design:Controlled, Double-blind, Randomized
Arms and Assigned Interventions
Descriptiondosage escalation of ADVAX
Mode of Delivery
ARMsExperimental
Official Code:
NCT00249106
Trial Sponsors:
Aaron Diamond AIDS Research Center, IAVI, University of Rochester
Start Date
End Date
December 31, 2003
October 31, 2005
Enrollment:45
Age range:
18 Years ↔
60 Years
Population:Cisgender Men, Cisgender Women